Navigating
Your Care

FIND A SOFT TISSUE SARCOMA SPECIALIST

Soft tissue sarcoma is considered a rare cancer, but that doesn’t mean you’re alone. Every year, approximately 12,000 people are diagnosed with soft tissue sarcoma in the United States.

Still, because it is rare, it is important to find a group of doctors who have experience diagnosing and treating this disease.

At sarcoma centers, you can find doctors who are experts in treating soft tissue sarcoma.

Doctors at sarcoma centers work as a team to find the best path forward for their patients. These centers may also help you connect with sarcoma support groups.

Get the Most Out
of Talking to
Your Doctor

Treatment decisions are a team effort between you and your doctor. The right questions can make all the difference in helping you understand your disease and your treatment options.

  • Don’t hesitate to speak up!

    You’re going to be hearing a lot of new information, so it’s normal to feel confused. It’s okay to have questions and ask your doctors to repeat what they have already said. They are there to help you with any questions or concerns, so don’t hold back!

  • TIP: Take notes or ask your doctor for permission to make an audio recording

    Bring a notebook or audio recorder to your visit. A friend or family member can help you with this.

    Most smartphones can make an audio recording, which can help you focus on listening during your visit. Review your doctor’s words at home whenever you need to.

    If you plan to make an audio recording of your conversation, make sure to ask your doctor for permission first.

YOU CAN ASK YOUR DOCTOR:

  • Who will be involved in my treatment?

  • What is your experience treating patients with sarcoma?

  • How often should I come in for additional tests or scans?

  • Can you recommend additional resources that would help educate me about my disease and treatment?

  • How will treatment affect my family, work, travel, etc?

  • Is LARTRUVO + doxorubicin right for me?

  • If LARTRUVO + doxorubicin is right for me, what can I expect during treatment?

  • What side effects should I expect with LARTRUVO + doxorubicin?

YOU CAN TELL YOUR DOCTOR:

  • If you are pregnant or breastfeeding, may be pregnant, or plan to become pregnant

  • If you are taking any medications, including prescription and over-the-counter medications

  • If you have received any past treatments for sarcoma or another type of cancer

  • If you have any other medical conditions

  • If you have ever experienced any allergic reactions or unusual responses to medication

BRING YOUR LIST OF QUESTIONS

Download and print the list above as a reminder during your visit.

INDICATION AND IMPORTANT SAFETY INFORMATION

EXPAND

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

X

You are now leaving the www.LARTRUVO.com website.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC, does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC, is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

  • Continue

  • Cancel

X

For US Healthcare Professionals

The information contained in www.LARTRUVO.com/hcp is technical in nature and intended for healthcare professionals in the United States only.

I'd like information for:

  • Healthcare Professionals

  • Patients and Caregivers